Should we still use high-dose melphalan in the era of novel agents? episode artwork

EPISODE · Feb 9, 2021 · 9 MIN

Should we still use high-dose melphalan in the era of novel agents?

from Multiple Myeloma Hub

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Nikhil C. Munshi, Dana-Farber Cancer Institute, Boston, US. We asked, Should we still use high-dose melphalan in the era of novel agents? In this podcast, Munshi discusses the role of high-dose chemotherapy combined with stem cell transplantation in the era of novel agents. Upon analyzing data from a genomic-focused study, he concludes that high-dose melphalan can still achieve good and deep responses, while maintenance therapy should also be an important treatment component for multiple myeloma. Hosted on Acast. See acast.com/privacy for more information.

Episode metadata supplied by the publisher feed · Published Feb 9, 2021

Embed this episode

NOW PLAYING

Should we still use high-dose melphalan in the era of novel agents?

0:00 9:54

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Multiple Myeloma Hub?

This episode is 9 minutes long.

When was this Multiple Myeloma Hub episode published?

This episode was published on February 9, 2021.

Can I download this Multiple Myeloma Hub episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!